ArticleNature immunology2024
Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption.
Erratum issuedAbstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Antiviral and anti-inflammatory effects of Cannabidiol in HIV/SIV infection.Brain, behavior, and immunity · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Review
- TGF-β mediates epigenetic control of innate antiviral responses and SIV reservoir size.Nature immunology · 2026Article
- Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.The Journal of clinical investigation · 2026Article
- Immune checkpoint inhibitors in HIV infection: current evidence on viral reservoir regulation and immune restoration.Frontiers in immunology · 2026Review
- HIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies.Current HIV research · 2026Review
- A novel diagnostic model for HIV-HTN comorbidity: genomic discovery, clinical validation, and mechanistic elucidation.Frontiers in medicine · 2026Article
- Mechanisms of Interleukin-10-Mediated Immunosuppression in Viral Infections.Pathogens (Basel, Switzerland) · 2025Review
- Prospects for therapeutic T-cell vaccine strategies for HIV cure.Current opinion in HIV and AIDS · 2025Review
- Understanding the HIV-specific T-cell response to immune checkpoint blockade: what can we learn from cancer immunotherapy?Current opinion in HIV and AIDS · 2025Review
- Novel insights into immune checkpoints in HIV/SHIV infection: from SHIVJournal of virology · 2025Article
- Host-directed approaches in the pursuit of a cure for HIV.Antiviral research · 2025Review
- Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.Journal of virology · 2025Review
- Immune Alterations and Viral Reservoir Atlas in SIV-Infected Chinese Rhesus Macaques.Infectious disease reports · 2025Review
- From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy.Immunotherapy · 2025Review
- Post-intervention control in HIV immunotherapy trials.Current opinion in HIV and AIDS · 2025Review
- Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption.Nature immunology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
30 authors.
Susan Pereira Ribeiro *Pathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Zachary Strongin *Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Hugo SoudeynsPathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Felipe Ten-CatenPathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-7771-1490
Khader GhneimPathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Gabriela Pacheco SanchezPathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Giuliana Xavier de MedeirosPathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Perla Mariana Del Rio EstradaPathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3366-3268
Adam-Nicolas PelletierRPM Bioinfo Solutions, Blainville, Québec, Canada.
Timothy HoangDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Kevin NguyenDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Justin HarperDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Sherrie JeanDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Chelsea WallaceDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Robert BalderasBecton Dickinson, San Jose, CA, USA.ORCID http://orcid.org/0000-0002-8734-8629
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Gopalan RaghunathanDepartment of Discovery Biologics, Merck & Co. Inc., South San Francisco, CA, USA.
Eric RimmerDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co. Inc., South San Francisco, CA, USA.
Cinthia V PastuskovasDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co. Inc., South San Francisco, CA, USA.
Guoxin WuDepartment of Quantitative Biosciences, Merck & Co. Inc., Rahway, NJ, USA.
Luca MicciDepartment of Discovery Oncology, Merck & Co. Inc., Boston, MA, USA.
Ruy M RibeiroTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0002-3988-8241
Chi Ngai ChanVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA.ORCID http://orcid.org/0000-0001-9106-9481
Jacob D EstesVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA.
Guido SilvestriPathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-6602-2470
Daniel M GormanDepartment of Discovery Biologics, Merck & Co. Inc., South San Francisco, CA, USA.
Bonnie J HowellDepartment of Quantitative Biosciences, Merck & Co. Inc., Rahway, NJ, USA.
Daria J HazudaDepartment of Quantitative Biosciences, Merck & Co. Inc., Rahway, NJ, USA.
Mirko PaiardiniPathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA. mirko.paiardini@emory.edu.ORCID http://orcid.org/0000-0002-7276-3600
Rafick P SekalyPathology Advanced Translational Research Unit (PATRU), Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA. rafick.sekaly@emory.edu.ORCID http://orcid.org/0000-0002-7816-4828
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0MReversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0MNonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1MViral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2018 to 2026
$17.5MHarnessing IL-10 in cART treated SIV infected macaques to restore immunity and to eradicate HIVR37AI141258 · NIAID · EMORY UNIVERSITY · PI Rafick Pierre Sekaly · 2018 to 2026
$7.8MMultiOMICS to uncover immune and virological mechanisms that drive HIV DNA decay, restore immune homeostasis, and promote HIV specific immunity in PWH receiving cell therapies.P01AI178376 · NIAID · EMORY UNIVERSITY · PI Rafick Pierre Sekaly · 2023 to 2026
$6.1MNCI NIH HHS 75N91019D00024NIAID NIH HHS P01 AI178376NIAID NIH HHS P30 AI050409NIAID NIH HHS R37 AI141258NIAID NIH HHS U24 AI126683NIAID NIH HHS UM1 AI164561NIAID NIH HHS UM1 AI164562NIH HHS P51 OD011132NIH HHS U42 OD011023
Abstract
Human immunodeficiency virus (HIV) persistence during antiretroviral therapy (ART) is associated with heightened plasma interleukin-10 (IL-10) levels and PD-1 expression. We hypothesized that IL-10 and PD-1 blockade would lead to control of viral rebound following analytical treatment interruption (ATI). Twenty-eight ART-treated, simian immunodeficiency virus (SIV)mac
Indexed as
CD8-Positive T-LymphocytesInterleukin-10Macaca mulattaProgrammed Cell Death 1 ReceptorSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral LoadAnimalsCD4-Positive T-LymphocytesTreatment InterruptionInterleukin-10Programmed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.